By examining the expression profiling characteristics of non-lesional (NL)/lesional (LS) skin before treatment of clinical trial drug TYK2/JAK inhibitor (PF-06700841) and lesional skin that pre/post treatment in patients with psoriasis, an integrated approach combining analysis of differentially expressed genes (DEGs) and WGCNA based on clinical features was employed. This evidence concerns the gene TYK2 and psoriasis.